Unusual case of a sigmoid mass.
BACKGROUND
Endometrial carcinoma is a relatively common condition which may occur with more than 6,400 new cases diagnosed each year in the UK (Cancer Research UK Statistics http://info.cancerresearchuk.org/cancerstats/types/uterus ). It may occur following hysterectomy especially if associated with prolonged hormone replacement therapy.


METHODS
We report the case of a 63-year-old lady who presented with a tumour in the sigmoid mesentery 13 years after hysterectomy and following 10 years of tamoxifen therapy for a breast carcinoma. This is the first time that endometrial cancer has been reported as a complication of tamoxifen therapy in the absence of a uterus.


CONCLUSIONS
We suggest that endometrial carcinoma remains a differential diagnosis of any pelvic or abdominal mass even after hysterectomy, and a history of intake of oestrogen agonists and antagonists needs to be obtained.
Grimes
Caris
C
Princess Alexandra Hospital NHS Trust, Hamstel Road, Harlow, Essex CM20 1QX, UK. carisgrimes@doctors.org.uk
Lalude
Olatunde
O
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery; D003937:Diagnosis, Differential; D016889:Endometrial Neoplasms / Q000473:pathology* / Q000601:surgery; D004715:Endometriosis / Q000150:complications / Q000601:surgery; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008408:Mastectomy; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000473:pathology* / Q000601:surgery; D012811:Sigmoid Neoplasms / Q000473:pathology* / Q000601:surgery; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen